Annual results show sales shrinking alongside a persistent loss structure. Revenue fell from KRW 68.9 billion in 2022 to KRW 63 billion in 2023 (down 8.6% year on year), KRW 62.7 billion in 2024 (down 0.4%), and KRW 59.3 billion in 2025 (down 5.4%).
Among 2022 to 2025, 2022 was the largest revenue year and 2025 the smallest. Operating loss widened from KRW 482 million in 2022 to KRW 6.83 billion in 2023 and KRW 9.65 billion in 2024, then narrowed to KRW 6.6 billion in 2025.
The operating margin moved from -0.7% in 2022 to -10.9% in 2023, -15.4% in 2024, and -11.1% in 2025.
Net income attributable to controlling shareholders swung from KRW 561 million in 2022 to a loss of KRW 10.5 billion in 2023, then losses of KRW 9.6 billion in 2024 and KRW 6.81 billion in 2025, with the loss narrowing in the latter two years.
Net income including non-controlling interests, a separate measure, was a loss of KRW 7.36 billion in 2025. Operating cash flow was -KRW 1.44 billion in 2022, -KRW 1.48 billion in 2023, -KRW 4.47 billion in 2024, and -KRW 4.18 billion in 2025.
On a quarterly basis, revenue moved from KRW 15.5 billion in Q3 2025 and KRW 15.8 billion in Q4 2025 to KRW 14.7 billion in Q1 2026, KRW 15.2 billion in Q2 2026, and KRW 13.8 billion in Q3 2026, with Q3 2026 down 10.7% year on year.
Operating loss went from KRW 1.49 billion in Q3 2025 and KRW 1.5 billion in Q4 2025 to KRW 1.12 billion in Q1 2026, KRW 23.01 million in Q2 2026, and KRW 251 million in Q3 2026. Operating losses have been recorded in each of the five quarters from Q3 2025 through Q3 2026.
Net income attributable to controlling shareholders turned positive at KRW 26.14 million in Q1 2026 and reached KRW 500 million in Q2 2026, before a net loss of KRW 246 million in Q3 2026. The sum of net losses attributable to controlling shareholders over the last four quarters is KRW 2.78 billion.
The company attributed the failure of 2025 earnings to rebound to raw material cost increases, intensifying generic competition, and drug price cuts occurring together.
The standalone Q3 2026 operating profit of KRW 145.75 million was reported by the media on November 17, 2026, while the consolidated cumulative operating loss of KRW 1.39 billion remains.